Skip to main content
. 2017 Dec 14;9(3):77–87. doi: 10.1177/2040622317743486

Figure 2.

Figure 2.

ASAS40 and 20 responses to biologic DMARDs (bDMARDs) in ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) in phase III clinical trials.

Direct comparison is limited given that there are no head-to-head studies comparing biologics. Partly adapted from Sieper et al.5

DMARD, disease modifying antirheumatic drug.